{"id":796,"date":"2026-08-01T03:29:37","date_gmt":"2026-08-01T07:29:37","guid":{"rendered":"https:\/\/www.durhampeptides.ca\/post\/what-is-thymosin-alpha-1"},"modified":"2026-10-21T12:04:33","modified_gmt":"2026-10-21T16:04:33","slug":"what-is-thymosin-alpha-1","status":"publish","type":"post","link":"https:\/\/www.durhampeptides.ca\/fr\/post\/what-is-thymosin-alpha-1","title":{"rendered":"What Is Thymosin Alpha-1? A Research Guide"},"content":{"rendered":"<p>Thymosin Alpha-1 is a 28-amino-acid peptide, CAS 62304-98-7, originally isolated from thymic tissue \u2014 the gland that trains T-cells during immune development. It is one of the few research peptides with a genuine clinical history behind it rather than only preclinical work, and it is also one of the most reliably confused with a completely different molecule.<\/p>\n<h2>The naming problem, first<\/h2>\n<p>Thymosin Alpha-1 and <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/tb-500-10mg\/\" target=\"_blank\" rel=\"noreferrer\">Thymosin Beta-4<\/a><\/u> are not variants of each other. They are unrelated peptides that happen to have been isolated from the same tissue fraction in the 1960s and 70s, and were named by which chromatographic fraction they appeared in rather than by any structural relationship.<\/p>\n<table><tr><td><p><\/p><\/td><td><p><strong>Thymosin Alpha-1<\/strong><\/p><\/td><td><p><strong>Thymosin Beta-4 (TB-500)<\/strong><\/p><\/td><\/tr><tr><td><p>Length<\/p><\/td><td><p>28 amino acids<\/p><\/td><td><p>43 amino acids<\/p><\/td><\/tr><tr><td><p>N-terminus<\/p><\/td><td><p>Acetylated<\/p><\/td><td><p>Acetylated<\/p><\/td><\/tr><tr><td><p>Primary research area<\/p><\/td><td><p>Immune modulation, T-cell maturation<\/p><\/td><td><p>Actin sequestration, tissue repair, angiogenesis<\/p><\/td><\/tr><tr><td><p>Binding partner<\/p><\/td><td><p>Toll-like receptors<\/p><\/td><td><p>G-actin<\/p><\/td><\/tr><tr><td><p>Clinical status<\/p><\/td><td><p>Approved in ~35 countries as Zadaxin<\/p><\/td><td><p>No approved indication<\/p><\/td><\/tr><\/table>\n<p>They share a name prefix and an acetylated N-terminus. That is the extent of it. A researcher choosing between them is not choosing a dose or a strength \u2014 they are choosing between two entirely different mechanisms.<\/p>\n<h2>How Thymosin Alpha-1 is understood to work<\/h2>\n<p>The peptide acts on innate immune signalling rather than on a single downstream target. The best-characterised interaction is agonism at Toll-like receptors \u2014 TLR2 and TLR9 in particular \u2014 on dendritic cells and monocytes. Activating those receptors shifts dendritic cell maturation, which in turn influences how naive T-cells differentiate.<\/p>\n<p>The practical framing in the literature is that Thymosin Alpha-1 does not suppress or stimulate immunity in a single direction. It is described as an immune modulator: in models of immune suppression it tends to restore T-cell responsiveness, while in models of excessive inflammation it has been reported to dampen the response. That bidirectional behaviour is unusual and is the main reason the peptide has held research interest for four decades.<\/p>\n<h2>Research history<\/h2>\n<p>Thymosin Alpha-1 has been studied in chronic hepatitis B and C, in sepsis, in immune reconstitution during chemotherapy, and as a vaccine adjuvant in elderly populations where response to vaccination is blunted. It is approved and marketed as Zadaxin in roughly 35 countries, though not in Canada or the United States.<\/p>\n<p>That regulatory position is worth understanding correctly. Approval elsewhere means the peptide has passed safety and efficacy review in those jurisdictions for specific indications \u2014 it does not mean it is approved here, and material sold by a research supplier in Canada is supplied for laboratory research only.<\/p>\n<h2>What the dosage literature describes<\/h2>\n<p>Clinical studies of Zadaxin have typically used a fixed subcutaneous dose administered twice weekly over extended courses, rather than weight-scaled dosing. Those figures come from approved-indication protocols in jurisdictions where the drug is licensed, under medical supervision, and they are not a template for anything else.<\/p>\n<p>For laboratory work the controllable variable is concentration. A 10mg vial reconstituted with 2mL of bacteriostatic water yields 5mg\/mL; with 5mL, 2mg\/mL. Choose the volume that puts your working concentration where the protocol needs it.<\/p>\n<h2>Handling and storage<\/h2>\n<ul><li><strong>Sealed and lyophilized:<\/strong> 2\u20138\u00b0C protected from light; \u221220\u00b0C for long-term storage.<\/li><li><strong>Reconstitution:<\/strong> <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/bacteriostatic-water-10ml\/\" target=\"_blank\" rel=\"noreferrer\">eau bact\u00e9riostatique<\/a><\/u>, sold separately. Add slowly down the vial wall \u2014 do not shake, as agitation can denature peptides at the air-liquid interface.<\/li><li><strong>After reconstitution:<\/strong> refrigerated, used within an appropriate research timeframe.<\/li><li><strong>Verification:<\/strong> Janoshik-tested batches carry a unique report key you can confirm independently.<\/li><\/ul>\n<p><strong>Is Thymosin Alpha-1 the same as TB-500?<\/strong><\/p>\n<p>No. TB-500 refers to Thymosin Beta-4, a 43-amino-acid peptide studied in tissue repair and angiogenesis through <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/tb-500-frag-17-23-10mg\/\" target=\"_blank\" rel=\"noreferrer\">actin binding<\/a><\/u>. Thymosin Alpha-1 is a 28-amino-acid immunopeptide studied in T-cell maturation and Toll-like receptor signalling. They are unrelated molecules that share a naming convention from the era they were isolated.<\/p>\n<p><strong>What are Thymosin Alpha-1's reported effects?<\/strong><\/p>\n<p>The research literature describes immune modulation rather than a single directional effect \u2014 restoration of T-cell responsiveness in immunosuppressed models, and dampening of excessive inflammatory response in others. It has been studied in chronic viral hepatitis, sepsis, and as a vaccine adjuvant.<\/p>\n<p><strong>Is Thymosin Alpha-1 approved anywhere?<\/strong><\/p>\n<p>Yes, as Zadaxin in approximately 35 countries for specific indications including chronic hepatitis B. It is not approved in Canada or the United States, and research-grade material is supplied for laboratory use only.<\/p>\n<p><strong>Is it available in Canada?<\/strong><\/p>\n<p>Yes. Durham Peptides stocks <u><a href=\"https:\/\/www.durhampeptides.ca\/fr\/product-page\/thymosin-alpha-1-10mg\/\" target=\"_blank\" rel=\"noreferrer\">Thymosin Alpha-1 10mg<\/a><\/u> domestically, with same-business-day shipping on orders placed and paid before 3:00 PM EST.<\/p>","protected":false},"excerpt":{"rendered":"Thymosin Alpha-1 is a 28-amino-acid peptide, CAS 62304-98-7, originally isolated from thymic tissue \u2014 the gland that trains T-cells during immune development. It is one of the few research peptides with a genuine clinical history behind it rather than only preclinical work, and it is also one of the most reliably confused with a completely different molecule. The naming problem, first Thymosin Alpha-1 and Thymosin Beta-4 are not variants of each other. They are unrelated peptides that happen...","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53,55],"tags":[],"class_list":["post-796","post","type-post","status-publish","format-standard","hentry","category-peptide-guides","category-research-science"],"_links":{"self":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/comments?post=796"}],"version-history":[{"count":1,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/796\/revisions"}],"predecessor-version":[{"id":1137,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/posts\/796\/revisions\/1137"}],"wp:attachment":[{"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/media?parent=796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/categories?post=796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.durhampeptides.ca\/fr\/wp-json\/wp\/v2\/tags?post=796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}